These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9718276)

  • 41. Differential activation of Gq/11 and Gi(3) proteins at 5-hydroxytryptamine(2C) receptors revealed by antibody capture assays: influence of receptor reserve and relationship to agonist-directed trafficking.
    Cussac D; Newman-Tancredi A; Duqueyroix D; Pasteau V; Millan MJ
    Mol Pharmacol; 2002 Sep; 62(3):578-89. PubMed ID: 12181434
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors.
    Olianas MC; Concas D; Onali P
    Br J Pharmacol; 2006 Feb; 147(4):360-70. PubMed ID: 16402046
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterization of receptor-mediated [35S]GTPgammaS binding to cortical membranes from postmortem human brain.
    González-Maeso J; Rodríguez-Puertas R; Gabilondo AM; Meana JJ
    Eur J Pharmacol; 2000 Feb; 390(1-2):25-36. PubMed ID: 10708703
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fish somatostatin sst3 receptor: comparison of radioligand and GTPgammaS binding, adenylate cyclase and phospholipase C activities reveals different agonist-dependent pharmacological signatures.
    Siehler S; Nunn C; Zupanc GK; Hoyer D
    Auton Autacoid Pharmacol; 2005 Jan; 25(1):1-16. PubMed ID: 15659149
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The 5HT(1A) receptor ligand, S15535, antagonises G-protein activation: a [35S]GTPgammaS and [3H]S15535 autoradiography study.
    Newman-Tancredi A; Rivet J; Chaput C; Touzard M; Verrièle L; Millan MJ
    Eur J Pharmacol; 1999 Nov; 384(2-3):111-21. PubMed ID: 10611431
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 5-Hydroxytryptamine(1A) receptor-stimulated [(35)S]GTPgammaS binding in rat brain: absence of regional differences in coupling efficiency.
    Meller E; Li H; Carr KD; Hiller JM
    J Pharmacol Exp Ther; 2000 Feb; 292(2):684-91. PubMed ID: 10640306
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacology of quinpirole-stimulated [35S]GTPgammaS binding: discrepancy with receptor binding profile.
    Gilliland SL; Alper RH; Levant B
    Eur J Pharmacol; 2000 Mar; 392(3):125-8. PubMed ID: 10762663
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The in vivo pharmacological profile of a 5-HT1 receptor agonist, CP-122,288, a selective inhibitor of neurogenic inflammation.
    Gupta P; Brown D; Butler P; Ellis P; Grayson KL; Land GC; Macor JE; Robson SF; Wythes MJ; Shepperson NB
    Br J Pharmacol; 1995 Nov; 116(5):2385-90. PubMed ID: 8581273
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of full, partial and inverse CC chemokine receptor 3 agonists using [35S]GTPgammaS binding.
    Wan Y; Jakway JP; Qiu H; Shah H; Garlisi CG; Tian F; Ting P; Hesk D; Egan RW; Billah MM; Umland SP
    Eur J Pharmacol; 2002 Dec; 456(1-3):1-10. PubMed ID: 12450563
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacological characterisation of melatonin mt1 receptor-mediated stimulation of [35S]-GTPgammaS binding.
    Beresford IJ; Harvey FJ; Hall DA; Giles H
    Biochem Pharmacol; 1998 Nov; 56(9):1167-74. PubMed ID: 9802327
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Studies of micro-, kappa-, and delta-opioid receptor density and G protein activation in the cortex and thalamus of monkeys.
    Ko MC; Lee H; Harrison C; Clark MJ; Song HF; Naughton NN; Woods JH; Traynor JR
    J Pharmacol Exp Ther; 2003 Jul; 306(1):179-86. PubMed ID: 12676881
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An autoradiographic study of the influence of pindolol upon [35S]GTPgammaS binding in rat, guinea pig and human brain.
    Serrats J; Artigas F; Mengod G; Cortés R
    Int J Neuropsychopharmacol; 2004 Mar; 7(1):27-34. PubMed ID: 14720318
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ligand efficacy and potency at recombinant alpha2 adrenergic receptors: agonist-mediated [35S]GTPgammaS binding.
    Jasper JR; Lesnick JD; Chang LK; Yamanishi SS; Chang TK; Hsu SA; Daunt DA; Bonhaus DW; Eglen RM
    Biochem Pharmacol; 1998 Apr; 55(7):1035-43. PubMed ID: 9605427
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine.
    Phebus LA; Johnson KW; Zgombick JM; Gilbert PJ; Van Belle K; Mancuso V; Nelson DL; Calligaro DO; Kiefer AD; Branchek TA; Flaugh ME
    Life Sci; 1997; 61(21):2117-26. PubMed ID: 9395253
    [TBL] [Abstract][Full Text] [Related]  

  • 55. S 15535 and WAY 100,635 antagonise 5-HT-stimulated [35S]GTP gamma S binding at cloned human 5-HT1A receptors.
    Newman-Tancredi A; Chaput C; Verrièle L; Millan MJ
    Eur J Pharmacol; 1996 Jun; 307(1):107-11. PubMed ID: 8831111
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 5-HT1A receptor agonist properties of antipsychotics determined by [35S]GTPgammaS binding in rat hippocampal membranes.
    Odagaki Y; Toyoshima R
    Clin Exp Pharmacol Physiol; 2007; 34(5-6):462-6. PubMed ID: 17439416
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Delta opioid modulation of the binding of guanosine-5'-O-(3-[35S]thio)triphosphate to NG108-15 cell membranes: characterization of agonist and inverse agonist effects.
    Szekeres PG; Traynor JR
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1276-84. PubMed ID: 9400003
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.
    Esbenshade TA; Fox GB; Krueger KM; Baranowski JL; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan JB; Faghih R; Bennani YL; Williams M; Hancock AA
    Biochem Pharmacol; 2004 Sep; 68(5):933-45. PubMed ID: 15294456
    [TBL] [Abstract][Full Text] [Related]  

  • 59. F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine.
    John GW; Pauwels PJ; Perez M; Halazy S; Le Grand B; Verscheure Y; Valentin JP; Palmier C; Wurch T; Chopin P; Marien M; Kleven MS; Koek W; Assie MB; Carilla-Durand E; Tarayre JP; Colpaert FC
    J Pharmacol Exp Ther; 1999 Jul; 290(1):83-95. PubMed ID: 10381763
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Regulation of 5-HT(1A) receptor-stimulated [35S]-GtpgammaS binding as measured by quantitative autoradiography following chronic agonist administration.
    Hensler J; Durgam H
    Br J Pharmacol; 2001 Jan; 132(2):605-11. PubMed ID: 11159711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.